Central venous access devices in patients with hemophilia

Expert Review of Medical Devices

Volumn 2, Issue 6, 2005, Pages 699-711

  Valentino, Leonard A ^a   Kapoor, Mukesh ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Devices; Hemophilia; Infusion therapy; Veins; Venous access

Indexed keywords

ALTEPLASE; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 8 CONCENTRATE; CHLORHEXIDINE; FIBRIN GLUE; HEPARIN; POVIDONE IODINE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; SEALANT; SODIUM CHLORIDE; UROKINASE;

AIR EMBOLISM; ANTISEPSIS; BACTEREMIA; BLEEDING; BLOOD TRANSFUSION; BLOOD VESSEL PERFORATION; CAREGIVER; CATHETER INFECTION; CHILD CARE; CLEANING; CLINICAL TRIAL; COMPRESSION; CONSULTATION; CONTINUOUS INFUSION; COST BENEFIT ANALYSIS; COST CONTROL; DEEP VEIN THROMBOSIS; DEVICE INFECTION; DEVICE REMOVAL; DISEASE ASSOCIATION; DOPPLER ECHOGRAPHY; DRUG INFUSION; DRUG MEGADOSE; DRUG SELF ADMINISTRATION; EXTRAVASATION; FAMILY HISTORY; FOREIGN BODY; HAND WASHING; HEALTH CARE ACCESS; HEALTH CARE COST; HEART ARRHYTHMIA; HEART TAMPONADE; HEMATOMA; HEMATOTHORAX; HEMOPHILIA; HEMOSTASIS; HIGH RISK PATIENT; HOSPITAL COST; HUMAN; INFECTION PREVENTION; INFECTION RISK; INTERMETHOD COMPARISON; INTRAVENOUS CATHETER; JUGULAR VEIN; LOW DRUG DOSE; MEDIASTINUM; MEDICAL ASSESSMENT; META ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSTRUCTION; OCCUPATIONAL THERAPIST; PATIENT EDUCATION; PATIENT MONITORING; PATIENT SELECTION; PERFORATION; PERIOPERATIVE PERIOD; PHLEBOGRAPHY; PNEUMOTHORAX; PRACTICE GUIDELINE; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SELF CARE; SKIN ABRASION; SUBCLAVIAN VEIN CATHETER; SURGICAL TECHNIQUE; THROMBOPHILIA; THROMBOSIS; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; UNITED STATES; VEIN CATHETERIZATION; VEIN PUNCTURE; VENOUS THROMBOEMBOLISM; WOUND CARE;

EID: 28244441988     PISSN: 17434440     EISSN: 17452422     Source Type: Journal    
DOI: 10.1586/17434440.2.6.699     Document Type: Review

References (94)

1. Mannucci PM, Tuddenham EG. The hemophilias - from royal genes to gene therapy. N. Engl. J. Med. 344, 1773-1779 (2001).
2. Ewenstein BM, Valentino LA, Journeycake JM et al. Consensus recommendations for use of central venous access devices in haemophilia. Haemophilia 10, 629-648 (2004).
3. Larson E. Status of practice guidelines in the United States: CDC guidelines as an example. Prev. Med. 36, 519-524 (2003).
4. Galloway S, Bodenham A. Long-term central venous access. Br. J. Anaesth. 92, 722-734 (2004).
5. Hamilton H. Central venous catheters: choosing the most appropriate access route. Br. J. Nurs. 13, 862-870 (2004).
6. Ljung R. Central venous catheters in children with haemophilia. Blood Rev. 18, 93-100 (2004).
7. Ljung R. Central venous lines in haemophilia. Haemophilia 9(Suppl. 1), 88-92 (2003).
8. Wight J, Paisley S, Knight C. Immune tolerance induction in patients with haemophilia A with inhibitors: a systematic review. Haemophilia 9, 436-463 (2003).
9. Carlborg E, Astermark J, Lethagen S, Ljung R, Berntorp E. The Malmo model for immune tolerance induction: impact of previous treatment on outcome. Haemophilia 6, 639-642 (2000).
10. Hay CR. Hemophilia treatment. Immune tolerance induction: prospective clinical trials. Haematologica 85, 52-55 (2000).
11. Brackmann HH, Oldenburg J, Schwaab R. Immune tolerance for the treatment of Factor VIII inhibitors - twenty years' 'bonn protocol'. Vox Sang. 70(Suppl. 1), 30-35 (1996).
12. Teitel JM, Barnard D, Israels S, Lillicrap D, Poon MC, Sek J. Home management of haemophilia. Haemophilia 10, 118-133 (2004).
13. Ross-Degnan D, Soumerai SB, Avorn J, Bohn RL, Bright R, Aledort LM. Hemophilia home treatment. Economic analysis and implications for health policy. Int. J. Technol. Assess. Health Care 11, 327-344 (1995).
14. Valentino LA, Ewenstein B, Navickis RJ, Wilkes MM. Central venous access devices in haemophilia. Haemophilia 10, 134-146 (2004).
15. Allain JP. A boarding school for hemophiliacs: a model for the comprehensive care of hemophilic children. Ann. NY Acad. Sci. 240, 226-237 (1975).
16. Inwood MJ. Aids for hemophiliac children on a self-infusion program. J. Pediatr. 92, 78-79 (1978).
17. Markova I, Forbes CD, Rowlands A, Pettigrew A, Willoughby M. The haemophilic patient's self-perception of changes in health and life-style arising from self-treatment. Int. J. Rehabil. Res. 6, 11-18 (1983).
18. Schimpf K. The role of self-infusion treatment for the patient with haemophilia (author's transl). Blut 36, 63-71 (1978).
19. O'Grady NP, Alexander M, Dellinger EP et al. Guidelines for the prevention of intravascular catheter-related infections. The Hospital Infection Control Practices Advisory Committee, Center for Disese Control and Prevention, US Pediatrics. 110, E51 (2002).
20. Fijnheer R, Paijmans B, Verdonck LF, Nieuwenhuis HK, Roest M, Dekker AW. Factor V Leiden in central venous catheter-associated thrombosis. Br. J. Haematol. 118, 267-270 (2002).
21. Decker MD, Edwards KM. Central venous catheter infections. Pediatr. Clin. North Am. 35, 579-612 (1988).
22. Essex-Cater A, Gilbert J, Robinson T, Littlewood JM. Totally implantable venous access systems in paediatric practice. Arch. Dis. Child 64, 119-123 (1989).
23. Girvan DP, deVeber LL, Inwood MJ, Clegg EA. Subcutaneous infusion ports in the pediatric patient with hemophilia. J. Pediatr. Surg. 29, 1220-1223 (1994).
24. Pearson ML. Guideline for prevention of intravascular device-related infections. Hospital Infection Control Practices Advisory Committee. Infect. Control Hosp. Epidemiol. 17, 438-473 (1996).
25. Geraghty S, Kleinert D. Use and morbidity of venous access devices in patients with hemophilia. J. Intraven. Nurs. 21, 70-75 (1998).
26. Ingram J, Weitzman S, Greenberg ML, Parkin P, Filler R. Complications of indwelling venous access lines in the pediatric hematology patient: a prospective comparison of external venous catheters and subcutaneous ports. Am. J. Pediatr. Hematol. Oncol. 13, 130-136 (1991).
27. Mirro J Jr, Rao BN, Kumar M et al. A comparison of placement techniques and complications of externalized catheters and implantable port use in children with cancer. J. Pediatr. Surg. 25, 120-124 (1990).
28. Mirro J Jr, Rao BN, Stokes DC et al. A prospective study of Hickman/Broviac catheters and implantable ports in pediatric oncology patients. J. Clin. Oncol. 7, 214-222 (1989).
29. O'Keefe SJ, Burnes JU, Thompson RL. Recurrent sepsis in home parenteral nutrition patients: an analysis of risk factors. J. Parenter. Enteral Nutr. 18, 256-263 (1994).
30. Pegues D, Axelrod P, McClarren C et al. Comparison of infections in Hickman and implanted port catheters in adult solid tumor patients. J. Surg. Oncol. 49, 156-162 (1992).
31. Vora A, Lilleyman, JS. Vascular access in young hemophiliacs: use of indwelling central venous catheters. Int. J. Pediatr. Hematol. Oncol. 1, 521-527 (1994).
32. Povoski S. Long-term venous access. In: Cancer Management: A Multidisciplinary Approach. Pazdur R, Coia LR, Hoskins WJ, Wagman LD (Eds). SCP Communications, Inc., NY, USA, 897-908 (2003).
33. Centers for Disease Control and Prevention. Report on the Universal Data Collection Program. 6(2), 17 (2004).
34. Manco-Johnson M. Hemophilia management: optimizing treatment based on patient needs. Curr. Opin. Pediatr. 17, 3-6 (2005).
35. MASAC. MASAC Recommendations Regarding Central Venous Access Devices Induding Ports and Passports. (2001).
36. Joshi R, Barrett AJ, Wastell C, Gibberd FB. Use of a Hickman catheter for permanent venous access in a patient with severe haemophilia. Clin. Lab. Haematol. 4, 319-321 (1982).
37. Tarantino MD, Lail A, Donfield SM et al. Surveillance of infectious complications associated with central venous access devices in children with haemophilia. Haemophilia 9, 588-592 (2003).
38. Scatorchia G. Tunneled catheters. In: Central Venous Catheters. Ray C Jr (Ed.). Lippincott Williams & Wilkins, PA, USA, 73-86 (2001).
39. Ahmad I. Complications of central venous access devices. In: Central Venous Access. Ray C Jr (Ed.). Lippincott Williams & Wilkins, PA, USA, 151-164 (2001).
40. Male C, Chait P, Andrew M, Hanna K, Julian J, Mitchell L. Central venous line-related thrombosis in children: association with central venous line location and insertion technique. Blood 101, 4273-4278 (2003).
41. Tisnado J, Pieters, PC. Complications of central venous catheters. In: Venous Catheters: A Practical Manual. Pieters P, Tisnado J, Mauro MA (Eds). Thieme, NY, USA, 249-280 (2003).
42. Bollard CM, Teague LR, Berry EW, Ockelford PA. The use of central venous catheters (portacaths) in children with haemophilia. Haemophilia 6, 66-70 (2000).
43. Van Den Berg HM, Fischer K, Roosendaal G, Mauser-Bunschoten EP. The use of the Port-A-Cath in children with haemophilia - a review. Haemophilia 4, 418-420 (1998).
44. Blanchette VS, Al-Musa A, Stain AM, Ingram J, Fille RM. Central venous access devices in children with hemophilia: an update. Blood Coagul. Fibrinolysis 8(Suppl. 1), S11-S14 (1997).
45. Perkins JL, Johnson VA, Osip JM et al. The use of implantable venous access devices (IVADs) in children with hemophilia. J. Pediatr. Hematol. Oncol. 19, 339-344 (1997).
46. Chaiyakunapruk N, Veenstra DL, Lipsky BA, Saint S. Chlorhexidine compared with povidone-iodine solution for vascular catheter-site care: a meta-analysis. Ann. Intern. Med 136, 792-801 (2002).
47. Maki DG, Ringer M, Alvarado CJ. Prospective randomised trial of povidone-iodine, alcohol, and chlorhexidine for prevention of infection associated with central venous and arterial catheters. Lancet 338, 339-343 (1991).
48. O'Grady NP, Alexander M, Dellinger EP et al. Guidelines for the prevention of intravascular catheter-related infections. Centers for Disease Control and Prevention. MMWR Recomm. Rep. 51, 1-29 (2002).
49. Male C, Chait P, Ginsberg JS et al. Comparison of venography and ultrasound for the diagnosis of asymptomatic deep vein thrombosis in the upper body in children: results of the PARKAA study. Prophylactic Antithrombin Replacement in Kids with ALL treated with Asparaginase. Thromb. Haemost. 87, 593-598 (2002).
50. Hull J. Tunneled catheters and chest ports. In: Venous Catheters: A Practical manual. Pieters P, Tisnado J, Mauro MA (Eds). Thieme, NY, USA, 97-118 (2003).
51. Morado M, Jimenez-Yuste V, Villar A et al. Complications of central venous catheters in patients with haemophilia and inhibitors. Haemophilia 7, 551-556 (2001).
52. Tock B, Drohan W, Hess J, Pusateri A, Holcomb J, Macphee M. Haemophilia and advanced fibrin sealant technologies. Haemophilia 4, 449-455 (1998).
53. Blanchette VS, al-Musa A, Stain AM, Filler RM, Ingram J. Central venous access catheters in children with haemophilia. Blood Coagul. Fibrinolysis 7(Suppl. 1), S39-S44 (1996).
54. Collins PW, Khair KS, Liesner R, Hann IM. Complications experienced with central venous catheters in children with congenital bleeding disorders. Br. J. Haematol. 99, 206-208 (1997).
55. Domm JA, Hudson MG, Janco RL. Complications of central venous access devices in paediatric haemophilia patients. Haemophilia 9, 50-56 (2003).
56. Goldsmith JC, Boody B, Atkinson J. Central venous catheter related complications in children with hemophilia. Blood 872a (1995).
57. Hothi DK, Kelsall W, Baglin T, Williams DM. Bacterial endocarditis in a child with haemophilia B: risks of central venous catheters. Haemophilia 7, 507-510 (2001).
58. Li CH, Ou Y, Lee AC, So KT. Septic arthritis in hemophilia with central venous catheter: a case report. Pediatr. Hematol. Oncol. 17, 187-189 (2000).
59. Liesner RJ, Vora AJ, Hann IM, Lilleymann JS. Use of central venous catheters in children with severe congenital coagulopathy. Br. J. Haematol. 91, 203-207 (1995).
60. Manco-Johnson MJ, Nuss R, Geraghty S, Funk S, Kilcoyne R. Results of secondary prophylaxis in children with severe hemophilia. Am. J. Hematol. 47, 113-117 (1994).
61. McMahon C, Smith J, Khair K, Liesner R, Hann IM, Smith OP. Central venous access devices in children with congenital coagulation disorders: complications and long-term outcome. Br. J. Haematol. 110, 461-468 (2000).
62. Ragni MV, Hord JD, Blatt J. Central venous catheter infection in haemophiliacs undergoing prophylaxis or immune tolerance with clotting factor concentrate. Haemophilia 3, 90-95 (1997).
63. Rothschild C, Merckx J, Clairicia M, Dazet D, Torchet MF, Pertuiset N. Experiences with implantable venous access devices in haemophilia children treated intensively: a low rate of complications. Haemophilia 6, 276 (2000).
64. Santagostino E, Gringeri A, Muca-Perja M, Mannucci PM. A prospective clinical trial of implantable central venous access in children with haemophilia. Br. J. Haematol. 102, 1224-1228 (1998).
65. Vidler V, Richards M, Vora A. Central venous catheter-associated thrombosis in severe haemophilia. Br. J. Haematol. 104, 461-464 (1999).
66. Warrier I, Baird-Cox K, Luther JM. Use of central venous catheters in children with haemophilia: one haemophilia treatment centre experience. Haemophilia 3, 194-198 (1997).
67. Yee TT, Beeton K, Griffioen A et al. Experience of prophylaxis treatment in children with severe haemophilia. Haemophilia 8, 76-82 (2002).
68. Ljung R, van den Berg M, Petrini P et al. Port-A-Cath usage in children with haemophilia: experience of 53 cases. Acta Paediatr. 87, 1051-1054 (1998).
69. Ljung R, Tengborn L, Petrini P. The Feasbility of long-term venous access in children with hemophilia. Semin. Hematol. 31(Suppl. 2), 16-18 (1994).
70. Berrington A, Gould FK. Use of antibiotic locks to treat colonized central venous catheters. J. Antimicrob. Chemother. 48, 597-603 (2001).
71. Mermel LA, Farr BM, Sherertz RJ et al. Guidelines for the management of intravascular catheter-related infections. J. Intraven. Nurs. 24, 180-205 (2001).
72. Ragni M. Infectious and thrombotic complications of central venous catheters in hemophilia patients. Home Healtbcare Consultant (1998).
73. Blanchette VS, Al-Trabolsi H, Stain AM et al. High risk of cental venous line-associated thrombosis in boys with hemophilia. Blood 94, 234a (1999).
74. Buchanan GR, Miller K, Zajac JL. Upper venous system thrombosis in haemophilia patients with long-term implantable central venous catheters. Haemophilia 6, 271 (2000).
75. DiMichele DM, Kroner BL. The North American Immune Tolerance Registry: practices, outcomes, outcome predictors. Thromb. Haemost. 87, 7 (2002).
76. Ettingshausen CE, Kurnik K, Schobess R et al. Catheter-related thrombosis in children with hemophilia A: evidence of a multifactorial disease. Blood 99, 1499-1500 (2002).
77. Journeycake JM, Buchanan GR. Catheter-related thrombosis in children with hemophilia. Blood 99, 1500 (2002).
78. Journeycake JM, Quinn CT, Miller KL, Zajac JL, Buchanan GR. Catheter-related deep venous thrombosis in children with hemophilia. Blood 98, 1727-1731 (2001).
79. Price VE, Carcao M, Connolly B et al. A prospective, longitudinal study of central venous catheter-related deep venous thrombosis in boys with hemophilia. J. Thromb. Haemost. 2, 737-742 (2004).
80. Van Dijk K, van Den Berg HM, van der Born JG. Complication of Port-A-Cath (PAC) in children with severe haemophilia. Haemophilia 8, 488 (2002).
81. Lowell JA Bothe A Jr. Central venous catheter related thrombosis. Surg. Oncol. Clin. N. Am. 4, 479-492 (1995).
82. Smith JP. Thrombotic complications in intravenous access. J. Intraven. Nurs. 21, 96-100 (1998).
83. Journeycake JM, Buchanan GR. Thrombotic complications of central venous catheters in children. Curr. Opin. Hematol. 10, 369-374 (2003).
84. Brown SA, Aledort LM, Lee CA. Optimal treatment regimens for patients with bleeding disorders. Haemophilia 7, 313-320 (2001).
85. Medeiros D, Miller KL, Rollins NK, Buchanan GR. Contrast venography in young haemophiliacs with implantable central venous access devices. Haemophilia 4, 10-15 (1998).
86. Polderman KH, Girbes AR. Central venous catheter use Part 2: infectious complications. Intensive Care Med. 28, 18-28 (2002).
87. Semba CP, Deitcher SR, Li X, Resnansky L, Tu T, McCluskey ER. Treatment of ocduded central venous catheters with alteplase: results in 1,064 patients. J. Vasc. Interv. Radiol. 13, 1199-1205 (2002).
88. Whitman ED. Complications associated with the use of central venous access devices. Curr. Probl. Surg. 33, 309-378 (1996).
89. Polderman KH, Girbes AR. Central venous catheter use. Part 1: mechanical complications. Intensive Care Med 28, 1-17 (2002).
90. Pipe SW. The promise and challenges of bioengineered recombinant clotting factors. J. Thromb. Haemost. 3, 1692-1701 (2005).
91. Pipe SW, Saint-Remy JM, Walsh CE. New high-technology products for the treatment of haemophilia. Haemophilia 10(Suppl. 4), 55-63 (2004).
92. Miekka SI, Jameson T, Singh M et al. Novel delivery systems for coagulation proteins. Haemophilia 4, 436-442 (1998).
93. High K. Gene transfer for hemophilia: can therapeutic efficacy in large animals be safely translated to patients? J. Thromb. Haemost. 3, 1682-1691 (2005).
94. High KA. Gene transfer as an approach to treating hemophilia. Semin. Thromb. Hemost. 29, 107-120 (2003).